Gene and protein expression markers of response to combined antiangiogenic and epidermal growth factor targeted therapy in renal cell carcinoma

D. Tsavachidou-Fenner, N. Tannir, P. Tamboli, W. Liu, D. Petillo, B. Teh, Gordon Mills, E. Jonasch

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Background: Metastatic renal cell carcinoma (mRCC) patients treated with anti-vascular endothelial growth factor (VEGF) therapies demonstrate promising outcomes but not all patients benefit. Factors that predict response remain to be elucidated. Patients and methods: Nephrectomy material from 37 patients with mRCC receiving bevacizumab ± erlotinib was used for protein and gene expression assessment. Protein lysates were subjected to reverse-phase protein array profiling. RNA extracts were used to carry out gene expression microarray-based profiling. Normalized protein and gene expression data were correlated with overall survival (OS) and progression-free survival (PFS) using univariate Cox hazard model and linear regression. Immunoblotting was carried out to validate the results. Results: High protein levels of AMP-activated protein kinase and low levels of cyclin B1 (CCNB1) were associated with longer OS and PFS. Further validation revealed reduced expression and activation of phosphoinositide 3-kinase (PI3K) pathway components and cell cycle factors in patients with prolonged survival after therapy. Gene expression analysis revealed up-regulation of PI3K-and cell cycle-related pathways in patients with shorter PFS. Conclusions: The OS and PFS of bevacizumab ± erlotinib-treated patients with renal cell carcinoma were associated with changes in expression of protein and gene expression markers related to PI3K pathway and cell cycle signaling.

Original languageEnglish (US)
Pages (from-to)1599-1606
Number of pages8
JournalAnnals of Oncology
Volume21
Issue number8
DOIs
StatePublished - Jan 20 2010
Externally publishedYes

Fingerprint

Renal Cell Carcinoma
Epidermal Growth Factor
Gene Expression
Disease-Free Survival
1-Phosphatidylinositol 4-Kinase
Proteins
Cell Cycle
Survival
Proportional Hazards Models
Therapeutics
Cyclin B1
Protein Array Analysis
AMP-Activated Protein Kinases
Nephrectomy
Immunoblotting
Vascular Endothelial Growth Factor A
Linear Models
Up-Regulation
RNA

Keywords

  • Angiogenesis
  • Bevacizumab
  • Biomarker profiling
  • Gene expression arrays
  • Protein arrays
  • Renal cell carcinoma

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Gene and protein expression markers of response to combined antiangiogenic and epidermal growth factor targeted therapy in renal cell carcinoma. / Tsavachidou-Fenner, D.; Tannir, N.; Tamboli, P.; Liu, W.; Petillo, D.; Teh, B.; Mills, Gordon; Jonasch, E.

In: Annals of Oncology, Vol. 21, No. 8, 20.01.2010, p. 1599-1606.

Research output: Contribution to journalArticle

Tsavachidou-Fenner, D. ; Tannir, N. ; Tamboli, P. ; Liu, W. ; Petillo, D. ; Teh, B. ; Mills, Gordon ; Jonasch, E. / Gene and protein expression markers of response to combined antiangiogenic and epidermal growth factor targeted therapy in renal cell carcinoma. In: Annals of Oncology. 2010 ; Vol. 21, No. 8. pp. 1599-1606.
@article{05702fddbff54347802a76803d4432bc,
title = "Gene and protein expression markers of response to combined antiangiogenic and epidermal growth factor targeted therapy in renal cell carcinoma",
abstract = "Background: Metastatic renal cell carcinoma (mRCC) patients treated with anti-vascular endothelial growth factor (VEGF) therapies demonstrate promising outcomes but not all patients benefit. Factors that predict response remain to be elucidated. Patients and methods: Nephrectomy material from 37 patients with mRCC receiving bevacizumab ± erlotinib was used for protein and gene expression assessment. Protein lysates were subjected to reverse-phase protein array profiling. RNA extracts were used to carry out gene expression microarray-based profiling. Normalized protein and gene expression data were correlated with overall survival (OS) and progression-free survival (PFS) using univariate Cox hazard model and linear regression. Immunoblotting was carried out to validate the results. Results: High protein levels of AMP-activated protein kinase and low levels of cyclin B1 (CCNB1) were associated with longer OS and PFS. Further validation revealed reduced expression and activation of phosphoinositide 3-kinase (PI3K) pathway components and cell cycle factors in patients with prolonged survival after therapy. Gene expression analysis revealed up-regulation of PI3K-and cell cycle-related pathways in patients with shorter PFS. Conclusions: The OS and PFS of bevacizumab ± erlotinib-treated patients with renal cell carcinoma were associated with changes in expression of protein and gene expression markers related to PI3K pathway and cell cycle signaling.",
keywords = "Angiogenesis, Bevacizumab, Biomarker profiling, Gene expression arrays, Protein arrays, Renal cell carcinoma",
author = "D. Tsavachidou-Fenner and N. Tannir and P. Tamboli and W. Liu and D. Petillo and B. Teh and Gordon Mills and E. Jonasch",
year = "2010",
month = "1",
day = "20",
doi = "10.1093/annonc/mdp600",
language = "English (US)",
volume = "21",
pages = "1599--1606",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "8",

}

TY - JOUR

T1 - Gene and protein expression markers of response to combined antiangiogenic and epidermal growth factor targeted therapy in renal cell carcinoma

AU - Tsavachidou-Fenner, D.

AU - Tannir, N.

AU - Tamboli, P.

AU - Liu, W.

AU - Petillo, D.

AU - Teh, B.

AU - Mills, Gordon

AU - Jonasch, E.

PY - 2010/1/20

Y1 - 2010/1/20

N2 - Background: Metastatic renal cell carcinoma (mRCC) patients treated with anti-vascular endothelial growth factor (VEGF) therapies demonstrate promising outcomes but not all patients benefit. Factors that predict response remain to be elucidated. Patients and methods: Nephrectomy material from 37 patients with mRCC receiving bevacizumab ± erlotinib was used for protein and gene expression assessment. Protein lysates were subjected to reverse-phase protein array profiling. RNA extracts were used to carry out gene expression microarray-based profiling. Normalized protein and gene expression data were correlated with overall survival (OS) and progression-free survival (PFS) using univariate Cox hazard model and linear regression. Immunoblotting was carried out to validate the results. Results: High protein levels of AMP-activated protein kinase and low levels of cyclin B1 (CCNB1) were associated with longer OS and PFS. Further validation revealed reduced expression and activation of phosphoinositide 3-kinase (PI3K) pathway components and cell cycle factors in patients with prolonged survival after therapy. Gene expression analysis revealed up-regulation of PI3K-and cell cycle-related pathways in patients with shorter PFS. Conclusions: The OS and PFS of bevacizumab ± erlotinib-treated patients with renal cell carcinoma were associated with changes in expression of protein and gene expression markers related to PI3K pathway and cell cycle signaling.

AB - Background: Metastatic renal cell carcinoma (mRCC) patients treated with anti-vascular endothelial growth factor (VEGF) therapies demonstrate promising outcomes but not all patients benefit. Factors that predict response remain to be elucidated. Patients and methods: Nephrectomy material from 37 patients with mRCC receiving bevacizumab ± erlotinib was used for protein and gene expression assessment. Protein lysates were subjected to reverse-phase protein array profiling. RNA extracts were used to carry out gene expression microarray-based profiling. Normalized protein and gene expression data were correlated with overall survival (OS) and progression-free survival (PFS) using univariate Cox hazard model and linear regression. Immunoblotting was carried out to validate the results. Results: High protein levels of AMP-activated protein kinase and low levels of cyclin B1 (CCNB1) were associated with longer OS and PFS. Further validation revealed reduced expression and activation of phosphoinositide 3-kinase (PI3K) pathway components and cell cycle factors in patients with prolonged survival after therapy. Gene expression analysis revealed up-regulation of PI3K-and cell cycle-related pathways in patients with shorter PFS. Conclusions: The OS and PFS of bevacizumab ± erlotinib-treated patients with renal cell carcinoma were associated with changes in expression of protein and gene expression markers related to PI3K pathway and cell cycle signaling.

KW - Angiogenesis

KW - Bevacizumab

KW - Biomarker profiling

KW - Gene expression arrays

KW - Protein arrays

KW - Renal cell carcinoma

UR - http://www.scopus.com/inward/record.url?scp=77952240870&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952240870&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdp600

DO - 10.1093/annonc/mdp600

M3 - Article

C2 - 20089566

AN - SCOPUS:77952240870

VL - 21

SP - 1599

EP - 1606

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 8

ER -